Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy

Yonsei University82 enrolled

Overview

The purpose of this study is to compare the efficacy of iv PCA with fentanyl or sufentanil in patients undergoing laparoscopic nephrectomy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

Patients Undergoing Laparoscopic Nephrectomy

Interventions

Sufentanil groupDRUG

PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.

Fentanyl groupDRUG

PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. patients undergoing laparoscopic or robot-assisted laparoscopic nephrectomy (total or partial) 2. patient who want intravenous PCA for postoperative pain control Exclusion Criteria: 1. long-term use of opioid, pain reliever or tranquilizers 2. a history of DM neuritis 3. prolonged prothrombin time or activated partial thromboplastin time 4. impairment of cognitive function 5. obesity (BMI ≥ BMI 30 kg/m2)

Locations (1)

Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea

Seoul, South Korea

Outcomes

Primary Outcomes

Efficacy of iv PCA with fentanyl or sufentanil in patients undergoing laparoscopic nephrectomy: Incidence of postoperative nausea and vomiting (PONV)

Incidence of postoperative nausea and vomiting (PONV)

Time frame: 24 hrs after recovery room discharge

Secondary Outcomes

postoperative pain score

NRPS (numerical verbal rating score of pain)

Time frame: at arrival to recovery room, 30 minutes after arrival to recovery room, 1 hour after recovery room discharge, 6 hrs after recovery room discharge, 24 hrs after recovery room discharge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.